Case report shows symptom improvement with 1.5% ruxolitinib cream after standard therapies failed
A 72‑year‑old woman with refractory Benign Familial Pemphigus (Hailey‑Hailey disease) experienced persistent flares despite conventional management with antibiotics and topical/systemic corticosteroids. Treatment with topical ruxolitinib 1.5% cream was associated with clinical improvement in her symptoms. The report highlights the therapeutic challenge of refractory HHD and illustrates the potential for a topical JAK inhibitor to reduce disease activity in a difficult‑to‑treat case.
This single‑patient observation is hypothesis‑generating: topical ruxolitinib may offer benefit for refractory HHD, but evidence is limited to case reports. Larger, systematic studies are needed to confirm efficacy, define dosing and duration, and assess safety in this population before routine use can be recommended.
Curious to learn more? Read one of our November case reports today.
J Drugs Dermatol. 2025;24(11):1141-1143. doi:10.36849/JDD.9351
Blog write-up assisted by AI
